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Abstract
The basic mechanisms underlying acquired generalized muscle weakness and paralysis in critically ill patients remain poorly
understood and may be related to prolonged mechanical ventilation/immobilization (MV) or to other triggering factors such
as sepsis, systemic corticosteroid (CS) treatment and administration of neuromuscular blocking agents (NMBA). The present
study aims at exploring the relative importance of these factors by using a unique porcine model. Piglets were all exposed
to MV together with different combinations of endotoxin-induced sepsis, CS and NMBA for five days. Peroneal motor nerve
conduction velocity and amplitude of the compound muscle action potential (CMAP) as well as biceps femoris muscle
biopsy specimens were obtained immediately after anesthesia on the first day and at the end of the 5-day experimental
period. Results showed that peroneal nerve motor conduction velocity is unaffected whereas the size of the CMAP
decreases independently of the type of intervention, in all groups after 5 days. Otherwise, despite a preserved size, muscle
fibre specific force (maximum force normalized to cross-sectional area) decreased dramatically for animals exposed to MV in
combination with CS or/and sepsis. These results suggest that the rapid declines in CMAP amplitude and in force generation
capacity are triggered by independent mechanisms with significant clinical and therapeutic implications.
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Introduction
The severe neuromuscular dysfunction in critically ill intensive
care unit (ICU) patients is associated with significant morbidity
and mortality. The acquired myopathy, acute quadriplegic
myopathy (AQM), seen in critically ill patients is a common cause
underlying neuromuscular dysfunction in ICU patients and is
characterized by a general paralysis or weakness in all trunk and
limb muscles [1,2]. AQM is associated with a decreased
compound muscle action potential (CMAP) amplitude, related to
a decreased muscle membrane excitability [3], muscle fibre
atrophy and disrupted function of the contractile apparatus
related to a general decline in myofibrillar protein content and a
preferential partial or complete loss of myosin and myosin-
associated proteins [4,5].
The basic understanding of the mechanisms underlying the
impaired muscle function in ICU patients with AQM remains
insufficient. Primary disease and sepsis contribute to the weakness,
but there is heterogeneity of underlying diseases and pharmaco-
logical treatments among patients with similar outcomes. In this
context it is likely that several common components of ICU
treatment, such as prolonged mechanical ventilation with
subsequent immobilization (MV), administration of systemic
corticosteroid (CS) and/or neuromuscular blocking agents
(NMBA) are involved in the pathogenesis behind this disorder
[1,2,6]. These factors have all been proposed to be important
triggering factors [6,7], but their relative importance remains
unknown. There is therefore a compelling need for an exper-
imental ICU model in which these different factors can be studied
separately or in combination. Different experimental animal
models have been introduced that have given valuable insights
[8], but most of these animal models do not include concurrent
ICU conditions such as prolonged mechanical ventilation,
sedation, immobilization and sepsis together with common
interventions used in modern anesthesiology and intensive care,
i.e. systemic CS and NMBA administration [8].
This study aims at unravelling the relative importance of the
different factors triggering muscle paralysis in ICU patients. For
this purpose, we have used a unique experimental porcine ICU
model in an attempt to investigate the relative influence of MV,
sepsis, CS and NMBA during the early development of
neuromuscular dysfunction, i.e., piglets have been exposed to
various combinations of MV, endotoxin-induced sepsis, CS and
NMBA for a duration of five days [9,10,11]. It was initially
hypothesized that: (i) MV and sedation alone is sufficient to
decrease CMAP amplitude, muscle fibre size and contractile
function; and (ii) sepsis, CS and NMBA together with MV and
sedation, separately or in combination, will have a additive
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14negative effect on CMAP amplitude, muscle fibre size and
contractile function.
Methods
Animals
A detailed description of animals has been given elsewhere [9].
Briefly, 18 female domestic piglets (23–30 kg body weight) were
included (Table 1). Animals were sedated with medetomidine
(Dormitor vet 1 mg/ml, Orion Pharma AB, Stockholm, Sweden)
and zolazepam (Zoletil 250, Reading, Carros, France). After
arrival in the laboratory and preparing an iv line, 100 mg of
ketamine (Ketaminol vet 50 mg/ml, Intervet, Boxmeer, Nether-
lands) was administered. During the 5-day study period, the
animals were sedated using isoflurane inhalation (Abbott Labora-
tories, 0.8–1.3% end-tidal concentration) supplemented by
intravenous bolus doses of morphine and ketamine as needed.
After induction, the trachea was cannulated via a midline incision
and a trachestomy tube was placed distally to the cricothyroid
cartilage. All animals were then mechanically ventilated using
volume-controlled ventilation (Servo 300; Siemens Elema) with an
initial FiO2 of 0.21–0.30, an inspired tidal volume of 10 ml?kg
21
and a respiratory rate of 20 breaths per min, with an I:E ratio of
1:2 and inspiratory rise time of 5–10%. During the remaining
study period, the settings were adjusted carefully to maintain
arterial oxygen and carbon dioxide tensions within normal limits
and to avoid high airway pressures and risk of barotrauma.
Sedation was titrated to promote ventilator synchrony and inhibit
spontaneous breathing activity. Arterial and central venous
catheters were placed in the common carotid artery and the
internal jugular vein via a separate incision on the neck and under
antiseptic conditions. Arterial and central venous blood pressures,
airway pressures and volumes as well as dynamic compliance,
rectal temperature and standard three-lead ECG were continu-
ously monitored. For assessment of the hemodynamic conditions,
a Swan-Ganz standard thermodilution pulmonary artery catheter
was inserted through the internal jugular vein catheter and
advanced until the characteristic pulmonary artery pressure curve
was registered. Excessive heat loss was avoided by covering the
animals when necessary with a warming blanket. A urinary
catheter was placed in the urinary bladder for continuous
monitoring of urinary output. Arterial acid-base balance, oxygen
and carbon dioxide tensions, electrolytes and blood glucose
concentration were monitored using ABL 2 and OSM2 analyzers
(Radiometer) and a Glucometer (Bayer Health Care). A
continuous infusion of Ringer’s acetate at 2000–4000 ml.day
21
was given for fluid replacement together with a continuous
infusion of buffered glucose 2.5 mg?ml
21 adjusting the infusion
rate to maintain tight control of arterial blood glucose levels
between 4–8 mM, and to assure a urinary output of 25–50 ml?h
21
throughout the study period. Enteral feeding was not considered
practical in this model due to the relatively deep sedation, in some
cases paralysis and a small laparotomy used in some study
protocols. Previous attempts to provide additional calories with
parenteral nutrition solutions resulted in fat vacuolization in
muscle cells [4]. All wounds were carefully cleaned and closed by
standard sutures to avoid unwanted contamination. During the
whole study period, from day 2 each animal received prophylactic
streptomycin 750 mg?d
21 and benzylpenicillin 600 mg?d
21
(Streptocillin Vet, Boeringer-Ingelheim). The animals were
clinically monitored and cared for continuously for the entire
study period by one of the authors or by a nurse anesthetist
experienced in the care of piglets and knowledgeable about the
study protocol. Routine care included evaluation of sedation level,
changing position, suctioning, adjusting fluid administration, etc.
After initial preparation, animals were allowed to stabilize for one
hour. This study protocol was approved by the Karolinska
Institutet Ethical Committee on Animal Research (Permit
numbers: Dnr N71/98, N54/02 and N75/04).
Experiment
The animals were randomly assigned to one of the five groups:
MV, sepsis, NMBA, CS, and ALL. MV group refers to piglets
that were mechanically ventilated for five days. Sepsis group
refers to mechanically ventilated piglets in which endotoxemia
was induced by a continuous one-hour infusion of Escherichia
coli endotoxin, serotype O26:B6 (Sigma Labkemi), titrated to
effect with a mean total dose of 8 mg?kg
21. The infusion was
started at a low dose and titrated upward until a hemodynamic
response occurred consisting of a fall in arterial mean blood
pressure $30% from baseline, with an increase $50% in
pulmonary artery occlusion pressure from baseline. The infusion
was paused if the animals required fluid resuscitation or
administration of adrenalin for bradykardia and was then
restarted at a lower dose. If the animal required repeated
interventions the infusion could be terminated earlier than at one
hour, and if tolerated could run for up to four hours. Continuous
infusions of inotropic drugs were not used to support the
circulation. This regimen typically resulted in a 6 to 12 hour-
period of severe circulatory instability and oliguria (urinary
output ,25 ml?h
21). Animals surviving this period of septic
shock generally regained circulatory stability during the remain-
ing experimental period. NMBA group refers to mechanically
ventilated piglets in which a neuromuscular blocking agent was
administered as a continuous infusion of rocuronium (Esmeron,
Table 1. Animal treatment.
Group N Mean weight Survival
PaO2
(kPa)
Compliance
(ml/cm H20) BE (mmol/L) PP (cm H20) Endotoxin CS NMBA
MV 4 27.10 kg 5 days 18.8 22 3.8 28 - - -
Sepsis 4 25.60 kg 5 days 17.2 22 1.8 26 E. coli - -
CS 3 26.90 kg 5 days 17.3 26 5.2 23 - Hydrocortisone -
NMBA 3 26.00 kg 5 days 21.3 25 3.3 25 - - Rocuronium
ALL 4 26.80 kg 5 days 19.8 24 4.3 23 E. coli Hydrocortisone Rocuronium
MV (mechanical ventilation), sepsis (endotoxemia was induced by a continuous infusion of Escherichia coli endotoxin), NMBA (neuromuscular blocking agent, i.e.,
continuous infusion of rocuronium, 25 mg?h
21), CS (corticosteroid given as bolus doses of hydrocortisone 50 mg,63 daily) and ALL (MV+CS+sepsis+NMBA). N: number
of animals; BE: base excess; PP: peak pressure.
doi:10.1371/journal.pone.0020876.t001
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21 for 5 days while CS group refers to
mechanically ventilated piglets in which a corticosteroid was
given as bolus doses of 50 mg of hydrocortisone (Solu-Cortef,
Pfizer AB) administered three times daily throughout the
experiment. ALL group refers to piglets that were mechanically
ventilated for 5 days together with the induced-endotoxemia,
corticosteroid administration three times daily and continuous
systemic administration of a neuromuscular blocking agent.
Animals were euthanized by a lethal injection of pentobarbitone
to terminate the experiment.
Electrophysiology
The electroneurography (ENeG) analysis included peroneal
motor nerve conduction velocities and facial nerve motor nerve
distal latency recordings bilaterally on the first and final day (day 5)
of the experiment. The tibialis anterior muscles compound muscle
action potential (CMAP) amplitudes were recorded upon supra-
maximal stimulation of the motor nerve. The electromyography
(EMG) analysis included concentric needle EMG examination of
proximal hind limb muscles (m. biceps femoris and gluteus
maximus) bilaterally (Keypoint, Dantec/Natus, Skovlunde, Den-
mark).
Muscle Biopsies and Permeabilization of Fibres
Muscle biopsies were obtained using the percutaneous
conchotome method from the biceps femoris muscle at day 1
and 5 of the experiment for all the piglets. The initial biopsies on
day 1 were taken before the start of infusion of endotoxin, CS
and/or NMBA. Biopsy specimens were dissected into two parts.
One part was frozen in liquid nitrogen-chilled propane and
stored at 280uC. The other was placed in relaxing solution at
4uC, and bundles of ,50 fibres were dissected free and then tied
with surgical silk to glass capillary tubes at slightly stretched
lengths. The muscle bundles were then treated with skinning
solution (relaxing solution containing glycerol; 50:50 v/v) for
24 hours at 4uC, after which they were transferred to 220uC.
The muscle bundles were treated with sucrose, a cryo-protectant,
within 1–2 weeks for long-term storage [12]. After the sucrose
treatment, muscle bundles were detached from the capillary tubes
and snap frozen in liquid nitrogen-chilled propane and stored at
2160uC.
Single Permeabilized Muscle Fibre Experimental
Procedure
On the day of an experiment, a fibre segment 1 to 2 mm long
was left exposed to the experimental solution between connectors
leading to a force transducer (model 400A, Aurora Scientific)
and a lever arm system (model 308B, Aurora Scientific) [13].
The total compliance of the attachment system was carefully
checked and remained similar for all the single muscle fibres
tested (560.5% of the fibre length). The apparatus was mounted
on the stage of an inverted microscope (model IX70; Olympus).
W h i l et h ef i b r es e g m e n t sw e r ei nr e l a x i n gs o l u t i o n ,t h e
sarcomere length was set to 2.65–2.75 mm by adjusting the
overall segment length [14]. The diameter of the fibre segment
between the connectors was measured through the microscope at
a magnification of 6320 with an image analysis system prior to
the mechanical experiments. Fibre depth was measured by
recording the vertical displacement of the microscope nosepiece
while focusing on the top and bottom surfaces of the fibre. The
focusing control of the microscope was used as a micrometer.
Fibre cross-sectional area (CSA) was calculated from the
diameter and depth, assuming an elliptical circumference, and
was corrected for the 20% swelling that is known to occur during
skinning [13].
Relaxing and activating solutions contained (in mM) 4 Mg-
ATP, 1 free Mg
2+, 20 imidazole, 7 EGTA, 14.5 creatine
phosphate, and KCl to adjust the ionic strength to 180 mM.
The pH was adjusted to 7.0. The concentrations of free Ca
2+ were
10
29 M (relaxing solution) and 10
24.5 M (activating solution),
expressed as pCas (i.e., 2log [Ca
2+]). Apparent stability constants
for Ca
2+-EGTA were corrected for temperature (15uC) and ionic
strength (180 mM). The computer program of Fabiato [15] was
used to calculate the concentrations of each metal, ligand, and
metal-ligand complex.
At 15uC, immediately preceding each activation, the fibre was
immersed for 10–20 s in a solution with a reduced Ca
2+-EGTA
buffering capacity. This solution is identical to the relaxing
solution except that the EGTA concentration is reduced to
0.5 mM, which results in more rapid attainment of steady force
during subsequent activation.
Force. Force was calculated as the difference between the
maximal steady-state isometric force in activating solution and the
resting force measured in the same segment while in the relaxing
solution. Maximal force production was normalized to CSA and
termed specific force.
Unloaded shortening velocity. At pCa 4.5, once steady-
state isometric force was reached, a series of slacks of various
amplitudes were rapidly introduced (within 1–2 ms) at one end of
the fibre [16]. Slacks were applied at different amplitudes ranging
from 7 to 13% of the fibre length. The fibre was re-extended
between releases while relaxed in order to minimize changes in
sarcomere length. During the slack test, the time required to take
up the imposed release was measured from the onset of the length
step to the beginning of the tension redevelopment. A straight line
including four or more data points was fitted to a plot of release
length versus time, using least-squares regression. The slope of the
line divided by the fibre segment length was recorded as the
maximum unloaded shortening velocity for that fibre segment
(V0).
For contractile measurements, strict acceptance criteria were
applied. First, the sarcomere length was monitored during the
experiments, using a high-speed video analysis system (model
901A HVSL, Aurora Scientific). A muscle fibre was accepted and
included in the analyses: (i) if the sarcomere length of a single
muscle fibre changed ,0.10 mm between relaxation and maxi-
mum activation, (ii) if maximal force changed ,10% from first to
final activation, and if r of the slope (plot of release length versus
time) for V0 calculation was .0.96 [17].
After the mechanical measurements, each fibre was placed in
urea buffer (120 g urea, 38 g thiourea, 70 ml H20, 25 g mixed bed
resin, 2.89 g dithiothreitol, 1.51 g Trizma base, 7.5 g SDS,
0.004% bromophenol blue) in a plastic micro centrifuge tube
and stored at 280uC.
Myosin Heavy Chain (MyHC) isoform expression
Single muscle fibre MyHC isoform expression was determined
by 6% sodium dodecyl sulfatepolyacrylamide gel electrophoresis
(SDS-PAGE). Sample loads were kept small (equivalent to
,0.05 mm of fibre segment) to improve the resolution of the
MyHC bands (slow and fast MyHC: type I, IIa, IIx and IIb).
Electrophoresis was performed at 120 V for 24 h with a Tris–
glycine electrode buffer (pH 8.3) at 15uC (SE 600 vertical slab gel
unit, Hoefer Scientific Instruments). The gels were silver-stained
and subsequently scanned in a soft laser densitometer (Molecular
Dynamics) with a high spatial resolution (50 mm pixel spacing) and
4096 optical density levels.
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The biceps femoris muscle frozen samples were cut at their
greatest girth perpendicular to the longitudinal axis of muscle
fibres into 10-mm-thick cross-sections with a cryotome (2800
Frigocut E, Reichert-Jung) at 220uC. Sections were dissolved into
100 ml of urea buffer after centrifugation and heating (90uC for
2 minutes) and a volume of 4 ml was loaded on 12% SDS-PAGE.
The total acrylamide and Bis concentrations were 4% (wt/vol) in
the stacking gel and 12% in the running gel. The gel matrix
included 10% glycerol. Electrophoresis was performed for 5 h
with a Tris–glycine electrode buffer (pH 8.3) at 15uC (SE 600
vertical slab gel unit, Hoefer Scientific Instruments). The gels were
stained with Coomassie blue (0.5 g brilliant blue, 225 ml MeOH,
225 ml distilled H2O and 50 ml acetic acid), as this staining shows
high reproducibility and the ability to penetrate the gel and stain
all proteins present, i.e., allowing accurate quantitative protein
analyses. The gels were subsequently scanned to determine the
MyHC to actin ratio.
Statistical analysis
Data are presented as means 6 standard error of the means
(SEMs). Sigma Stat software (Jandel Scientific) was used to
generate descriptive statistics. For motor nerve conduction
velocities and compound muscle action potential amplitudes, a
two-way ANOVA (day6group) was applied followed by the
Tukey’s test. For single muscle fibre experiments, a total 365
fibres were included in the analyses (minimum of 10 acceptable
fibres per animal per day). Given the small number of hybrid
(type I/IIa and II/IIx) and pure IIb fibres observed in these
experiments, comparisons were restricted to fibres expressing the
type I, IIa and IIx MyHC isoforms. For CSA, specific force and
V0, a three-way ANOVA (day6group6fibre type) was performed
followed by the Tukey’s test. For the MyHC to actin ratio,
another two-way ANOVA (day6group) was carried out.
Otherwise, linear regression analysis for slack-test determination
and nonlinear regression for relative force-pCa curve fitting were
performed and relationships were considered significantly differ-
ent from zero at p,0.05.
Results
Electrophysiology
The average peroneal motor nerve conduction velocity varied
between 55 and 69 m?s
21 in the different groups on day 1 and
between 47 and 69 m?s
21 on day 5. No significant change in
motor nerve conduction velocity was observed in any of the groups
(MV, CS, NMBA and ALL). On the other hand, the CMAP
amplitude decreased (p,0.05) significantly after five days in all
groups irrespective of the type of intervention (Figure 1). The
largest relative decrease in the CMAP amplitude was observed in
the all treatment group. However, it should be mentioned that the
number of animals in the different groups was relatively small, due
to the extremely demanding experimental conditions, and thereby
reducing the power of the statistical analyses. Moreover, variability
between animals in CMAP amplitude was present. Such
variability may be primarily due to individual differences in
muscle size and conduction of the EMG signal thorough
subcutaneous and skin tissue. Nevertheless, here, CMAP ampli-
tude was compared within the same animals rather than between
animals during the 5-day observation period. Therefore, this
variability does not have any impact on the conclusions.
Single muscle fibre size and contractile function
A total of 365 fibres fulfilled the strict criteria for acceptance (see
Materials and Methods) and were included in the analyses. The
CSA was unchanged during the five-day period in mechanically
ventilated piglets irrespective of the type of intervention (MV, CS,
sepsis, NMBA and ALL) (Figure 2). On the other hand, a dramatic
decrease in single muscle fibre specific force (maximum force
normalized to CSA), irrespective MyHC isoform expression, was
observed in animals exposed to CS, sepsis and a combinationof CS,
sepsis and NMBA (p,0.05) (Figure 2). In single muscle fibres
separated according to MyHC isoform expression (types I, IIa and
IIx), the maximum unloaded shortening velocity (V0) did not
change over the five-day period in any of the groups, arguing
against a modification of myosin cross-bridge cycling kinetics
underlying the decreased specific force in animals exposed to
systemic CS administration or sepsis or both (Figure 2). It should be
Figure 1. Compound muscle action potential amplitudes. CMAP amplitudes on day 1 and day 5 (normalized to day 1 values) from
mechanically ventilated/sedated/immobilized (MV group) piglets, MV together with neuromuscular blocking agents (NMBA group), MV together with
corticosteroid administration (CS group), MV together an endotoxin-induced sepsis (sepsis), and MV together with sepsis, CS and NMBA (ALL group).
doi:10.1371/journal.pone.0020876.g001
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animals at day 1. This variability was not statistically significant.
The underlying mechanisms of this variability remain unknown but
are probably age-related. In fact, instead of testing adult pigs, piglets
were used (cost-related reasons). Maturation and aging are animal-
dependent and may potentially modulate CSA, specific force or V0.
Figure 2. Single muscle fibre size and contractile function. Cross-sectional area (CSA), specific force (maximal force production normalized to
CSA) and maximum unloaded shortening velocity (V0). Values for day 1 (empty colored bars) and day 5 (hatched colored bars) from mechanically
ventilated/sedated/immobilized (MV group) piglets, MV together with neuromuscular blocking agents (NMBA group), MV together with
corticosteroid administration (CS group), MV together an endotoxin-induced sepsis (sepsis), and MV together with sepsis, CS and NMBA (ALL group).
Data are presented as means 6 SEMs. Asterisk denotes a statistically significant difference compared with day 1 (p,0.05).
doi:10.1371/journal.pone.0020876.g002
Figure 3. Myosin:actin ratios. Values for day 1 (empty colored bars) and day 5 (hatched colored bars) from mechanically ventilated/sedated/
immobilized (MV group) piglets, MV together with neuromuscular blocking agents (NMBA group), MV together with corticosteroid administration (CS
group), MV together an endotoxin-induced sepsis (sepsis), and MV together with sepsis, CS and NMBA (ALL group). Data are presented as means 6 SEMs.
doi:10.1371/journal.pone.0020876.g003
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There was no preferential myosin loss in any of the groups
during the five day period, i.e. myosin:actin ratios were unaffected
in all groups (MV, sepsis, CS, NMBA and ALL groups) (Figure 3).
Discussion
In a previous pilot study we introduced the porcine ICU model
and demonstrated the feasibility of this model [9]. The present
study confirms and extends our previous pilot observations in a
larger group of animals exposed to different factors suggested as
triggers for acute quadriplegic myopathy in ICU patients. These
triggering factors (CS, NMBA and sepsis) were given separately
and in combination to sedated and mechanically ventilated
animals. Results show that MV, sedation and immobilization
with or without NMBA, CS and sepsis cause a decreased
amplitude of the CMAP. Muscle fibre size, measured in single
muscle cell segments at optimal sarcomere length for force
generation, was not affected in any of the groups independent of
intervention in accordance with our pilot observations [9].
However, a dramatic decrease in force generation capacity
(specific force) was observed in animals exposed to CS and sepsis,
separately or in combination.
A decreased amplitude of the CMAP, or an absent CMAP, is
considered a hallmark of AQM primarily reflecting a decreased
muscle membrane excitability [18]. However, other factors may
also cause a reduction of the CMAP amplitude, such as muscle
atrophy, axonal motor neuron loss, demyelinating neuropathy
with conduction block and temporal dispersion of the CMAP or
altered recording conditions related to e.g. subcutaneous edema.
Muscle atrophy and a demyelinating neuropathy seem highly
unlikely due to the maintained muscle fibre size and motor nerve
conduction velocity. A motor neuron loss in all groups cannot be
completely ruled out, but appears equally unlikely during this
relatively short observation period. In septic animals, we have
observed increased subcutaneous edema, but the edema was
primarily restricted to the craniofacial region and we have not
observed clinical signs of edema in the hind-limbs. Although
subcutaneous edema cannot be ruled out as a mechanism
underlying the reduced CMAP amplitude, an altered membrane
excitability appears to be more likely. In a series of elegant
experimental studies, Rich and co-workers [19,20,21] have
presented results showing that the most likely mechanisms
underlying the absent or low CMAP amplitudes in patients with
AQM are altered membrane excitability and defective sodium
channel regulation. Assuming the same mechanism underlying the
decreased CMAP amplitude in our porcine ICU model, the
present results suggest that inactivity per se is a very important
factor underlying the decreased CMAP in ICU patients with
AQM. This is further supported by the restoration of the
denervation induced change in muscle resting potential by muscle
activity [22].
Muscle contraction is severely deregulated in ICU patients
with AQM [4,5] due to an imbalance between the rate of protein
synthesis and degradation leading to a general myofibrillar
protein loss, a preferential loss of myosin and myosin-associated
thick filament proteins, muscle fibre atrophy and decreased force
[4]. In none of the groups included in this study were there any
signs of the preferential myosin loss considered to be a
pathognomonic finding in ICU patients with AQM [4]. This is
probably due to the relatively short duration of the experimental
five-day period. This is supported by recent findings from our
group using a rodent ICU model where animals were
mechanically ventilated, sedated and exposed to NMBA for
durations varying between six hours and two weeks. Similar
r e s u l t sw e r eo b s e r v e di nt h i sg r o u pa si nt h eM Va n dN M B A
groups in this study, i.e., there was no significant change in
maximum single muscle fibre force, myosin:actin ratio or cross-
sectional area during the first four days. However, at durations
longer than a week there was a progressive decline in specific
f o r c ea n df i b r es i z ei np a r a l l e lw i t hap r e f e r e n t i a lm y o s i nl o s s
(submitted manuscript). The dramatic decline in specific force in
animals exposed to sepsis or systemic steroid hormone treatment
during the five-day period without a preferential myosin loss
show that both sepsis and CS augment the effects of the ICU
intervention on skeletal muscle by impairing muscle function via
mechanisms distinct from altered muscle membrane properties
or a preferential myosin loss. This further supports the notion
that neither CS nor sepsis represents prerequisites for AQM, but
that they facilitate the development of this neuromuscular
disorder.
Both sepsis and CS are commonly associated with an increase in
circulating glucocorticoid levels [23]. Glucocorticoids are known
to exacerbate the deleterious effects of immobilization on muscle
structure and function [24]. Different intracellular mediators are
involved including Akt, mTOR, GSK-3b, b-catenin, FOXO,
REDD1 and ATF4 [25,26] and provoke a decrease in both the
rate of myofibrillar protein synthesis and degradation [25,26,27].
Thus, sepsis and CS may induce an early general loss of contractile
proteins, preceding atrophy and preferential myosin loss, resulting
in a decrease in specific force (Figure 2). In addition, increasing
circulating glucocorticoid levels induce an increase in the number
of reactive oxygen species [28] and oxidative stress mediated via
systemic corticosteroid hormone treatment and sepsis may
accordingly lead to post-translational modifications of contractile
proteins [29] with negative effects on protein function and
decreased specific force.
In conclusion, the present results show that different factors
trigger the decreased amplitude of the compound muscle action
potential and the decreased force generating capacity of skeletal
muscle in response to five days exposure to different experimental
ICU conditions. Immobilization in combination with sedation and
mechanical ventilation appear to be the key elements triggering
the lowering of the CMAP amplitude, probably via an effect on
muscle membrane excitability. Sepsis and systemic corticosteroid
hormone treatment, separately or in combination, decreased the
force generation capacity at the single muscle fibre level,
independent of muscle fibre type. However, muscle fibre size
was not affected by mechanical ventilation, immobilization,
sedation, neuromuscular blocking agents, sepsis or corticosteroids
during the five-day experimental period. Thus, the unique porcine
ICU model gives valuable insights into the mechanisms underlying
limb muscle weakness during the early phase of the ICU
intervention and is forwarded as a valuable model for further
mechanistic studies as well as in specific intervention studies.
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